Yeast Infection Treatment Market Growth Opportunities: Insights from 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Yeast Infection Treatment Market Over The Five-Year Period 2025–2029?

The market size for yeast infection treatment has shown substantial growth in recent years. It is expected to expand from $4.33 billion in 2024 to $4.62 billion in 2025, at a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be attributed to several factors, including the increased prevalence of yeast infections, a growing awareness regarding fungal infections, the aging population, a rise in global healthcare expenditure, and the development and approval of new antifungal medications.

The market size for yeast infection treatments is expected to undergo significant expansion in the upcoming years. It is projected to achieve a valuation of $5.74 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth over the forecast period can be linked to factors such as the increasing embrace of telemedicine for consultations from a distance, tailored medicine approaches for specific treatments, the appearance of combination therapies for better effectiveness, a growing focus on natural and herbal remedies, and an emphasis on microbiome-based therapies for managing infections. Notable trends during this period include advancements in genomic research, the creation of compact and accurate diagnostic equipment, technological progress in yeast infection diagnosis and treatment, increasing financial commitments to research and development, and the formation of strategic alliances.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13958&type=smp

Which Drivers Are Supporting Growth Of The Yeast Infection Treatment Market?

The increasing incidence of autoimmune diseases is anticipated to drive the expansion of the yeast infection treatment market in the future. An autoimmune disease is characterized by the immune system erroneously targeting healthy cells, tissues, and organs, leading to impaired bodily function and potentially life-threatening consequences. Yeast infection treatments play a role in both managing and averting complications associated with autoimmune diseases by tackling recurring yeast infections, often connected to specific autoimmune syndromes, and potentially by influencing the immune response through effective management of fungal infections in individuals suffering from autoimmune conditions. For example, data from March 2023, provided by the National Institutes of Health, a US-based federal agency dedicated to medical research, indicated that approximately 8.4 million individuals worldwide were projected to have type 1 diabetes (T1DM) in 2021, with an additional 500,000 new diagnoses reported during the same year. Furthermore, the estimated number of people with T1DM is projected to reach between 13.5 and 17.4 million by the year 2040. Consequently, the growing prevalence of autoimmune diseases is a significant factor propelling the expansion of the yeast infection treatment market.

What Are The Segment Types Shaping The Yeast Infection Treatment Market?

The yeast infection treatmentmarket covered in this report is segmented –

1) By Type: Powders; Creams Or Ointments; Tablets Or Capsules; Other Types

2) By Treatment: Medical Treatment; Surgery

3) By Indication: Genital Candidiasis; Invasive Candidiasis; Oropharyngeal Or Esophageal Candidiasis (Thrush); Other Indications

4) By Route Of Administration: Oral; Topical; IV (Intravenous) Or IM (Intramuscular); Other Routes Of Administration

5) By Application: Retail Pharmacies Or Drug Stores; Hospital Pharmacies; Specialty Stores; Online Sales; Other Applications

Subsegments:

1) By Powders: Antifungal Powders; Medicated Body Powders

2) By Creams Or Ointments: Antifungal Creams; Vaginal Ointments; Topical Creams

3) By Tablets Or Capsules: Oral Antifungal Tablets; Probiotic Capsules; Vaginal Tablets

4) By Other Types: Suppositories; Sprays; Gels

Which Market Trends Are Creating New Opportunities In The Yeast Infection Treatment Industry?

Leading companies in the yeast infection treatment market are concentrating on introducing innovative therapies or medications, such as non-azole oral antifungals, to gain a competitive edge. A non-azole oral antifungal is an orally administered medication that combats fungal infections without belonging to the azole class of antifungals. For instance, in December 2022, SCYNEXIS, a US-based biotechnology company, announced that BREXAFEMME (ibrexafungerp tablets) received approval from the United States Food and Drug Administration (FDA), a US-based federal agency, for its second indication. This innovative non-azole oral antifungal is the first FDA-approved treatment for both the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and the reduction in the incidence of recurrent VVC. It provides a novel alternative with broad-spectrum activity, influencing the dynamics of the yeast infection treatment market and addressing the limited options available for patients with recurrent VVC. The recommended dosage of BREXAFEMME for VVC treatment is 300 mg (two 150 mg tablets), given one day at a time, about 12 hours apart, for a total of 600 mg (four 150 mg tablets) every day.

Who Are The Prominent Global Companies Shaping The Yeast Infection Treatment Market?

Major companies operating in the yeast infection treatment market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/yeast-infection-treatment-global-market-report

How Is Yeast Infection Treatment Market Demand Varying Across Different Regions?

North America was the largest region in the yeast infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yeast infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Yeast Infection Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13958&type=smp

Browse Through More Reports Similar to the Global Yeast Infection Treatment Market 2025, By The Business Research Company

Neurofibromatosis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurofibromatosis-treatment-global-market-report

Optic Nerve Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Zollinger Ellison Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/zollinger-ellison-syndrome-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795